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Summary
Forty, individually fed, yearling steers
(750 lbs) were used to measure payout
characteristics of different tre nbolone acetate-
containing implants and to correlate those
characteristics  to growth response.
Treatments were 1) control, 2) Synovex-S®,
3) Finaplix-S®, 4) Synovex® plus Finaplix,
and 5) Revalor®.  Steers were fed a 12%
crude protein, corn-based, finishing diet for
112 days.  Compared to Revalor, which had
a fairly constant payout over time, the
combination  of Synovex plus Finaplix
resulted in higher blood levels of estradiol
and trenbolone acetate (TBA) up to 56 days,
followed by a relatively rapid declin e to 112
days.  Despite elevated levels of TBA at 112
days for all TBA-containing implants and
elevated estradiol at 112 days from Revalor
steers, implants did not improve performance
in the final 28 days before slaughter.  Short
(less than 120 days) feeding periods may
favor implants that increase blood levels of
anabolics  for shorter (56-84 day) periods.
Data for plasma urea nitrogen were inter-
preted to indicate that 12% cr ude protein was
adequate  for yearling steers gaining approx-
imately 3.5 lbs per day.
(Key Words:  Trenbolone Acetate, Estradiol,
Serum Hormones, Feedlot.)
Introduction
Anabolic  implants are proven, safe, and
effective management tools to enhance
profitability for cattle feeders.  In order to
optimize performance and maximize return,
implant programs should be custom designed
for each pen of cattle, based on cattle type,
projected days on feed, and market or
contract specifications for finished cattle.
Research  has shown that, in beef cattle,
maximal response to trenbolone acetate
(TBA) has generally been achieved when it
was administered in combination with an
estrogenic implant used once and admin-
istered as the terminal implant in the sched-
ule.  Recent K-State research indicated that
calf-fed Holstein steer performance is
enhanced with multiple TBA implants,
although carcass quality grade may be
reduced.  This places added importance on
knowing release rates from TBA-containing
implants, in order to maximize performance
and minimize negative effects on carcass
quality.  Estrogenic  implants also may reduce
carcass quality if administered too close to
slaughter (less than 60-65 days remaining on
feed).  Two TBA-containing implants are
commercially  available.  Finaplix-S contains
140 mg TBA in a lactose-carrie r , and Revalor
S contains 120 mg  TBA plus 24 mg estradiol
in a cholesterol-based implant.  Synovex-S
contains  20 mg estradiol benzoate and 200
mg progesterone.  We measured payout
characteristics  of these implants and corre-




Forty, crossbred, yearling, beef steers
(750 lbs) were penned individually and fed a
rolled corn finishing diet (10% roughage, dry
basis) that contained 12% crude protein.
Steers had been previously implanted with
Synovex-S and backgrounded on corn silage
for 90 days.  Previous implant s were removed
14 days before this study began.
Eight steers were assigned to each of five
implant treatments:  1) Control (no implant),
2) Synovex-S only (SYN), 3) Finaplix-S only
(FIN), 4) Synovex plus Finaplix used
together  (SYN + FIN), and 5) Revalor
(REV).   Blood samples were obtained twice
daily (30 minutes apart, before the morning
feeding)  on days 0, 14, 28, 42, 56, 84, and
112.  Serum was analyzed for estradiol,
trenbolone  acetate, and growth hormone.
Plasma was analyzed for urea nitrogen.  The
trial was conducted for 112 days (May 1 to
August 21, 1992).  Steers then were
slaughtered, and carcass characteristics were
measured.
Results and Discussion
As expected, serum trenbolone acetate
(TBA) concentrations were essentially zero
for control and SYN steers and lower
(P<.05) than those for t he other treatments at
all sampling times (Figure  1).  Serum concen-
trations of TBA were higher  (P<.10) in steers
implanted  with Finaplix vs Revalor for the
first 42-56 days of the study, then declined.
At 84 days, TBA levels were similar for
steers implanted with Finapl ix or Revalor, but
were higher (P<.10) at 112 days for Revalor
steers.  Thus, TBA in Revalor apparently
pays out at a fairly constant rate (at least to
112 days), whereas payout from Finaplix is
characterized by a more rapid release for the
first 42-56 days, followed by a decline.
Changes in serum estradiol concentra-
tions (Figure 2), although somewhat more
variable, show similar trends.  Estradiol in
Revalor-implanted steers remained relatively
constant  throughout the 112 days.  Con-
versely, estradiol was elevated for SYN+FIN
steers for approximately 84 days, then
dropped rapidly.  Serum estradiol levels were
higher for SYN+FIN vs SYN steers
throughout  the first 84 days of the study.
Although the reason for t his synergistic effect
is not entirely clear, we know that significant
amounts  of TBA can be converted to
estradiol in the body.  A lternatively, TBA can
displace estradiol from receptor sites, thus
increasing circulating  estradiol concentration.
In our study, implant type did not affect
serum growth hormone or plasma urea
concentrations.  Generally, implantation with
estradiol has been associated with increased
blood concentrations of growth hormone,
although most of that work has been done
with younger animals.  These data indicate
that some factor other than increased growth
hormone is responsible f or growth promotion
by anabolic implants.  Time on feed had
significant  effects on growth hormone and
plasma urea nitrogen (Figure 3).  Growth
hormone concentration decreased linearly
(P<.01) with time on feed, as animals
approached  physiological maturity.  Plasma
urea nitrogen increased (P<.01) with time on
feed.  This might be interpreted to indicate
that 12% crude protein progressively
exceeded  the protein requirement of the
steers during the finishing period, because
elevated plasma urea is associated with
protein wastage.  Further, the lack of an
implant effect or implant ×  time interaction
suggests that 12% crude protein (50%
soybean meal N:50% urea N) met or
exceeded  the protein requirements for
implanted  steers in this study.  Compared to
nonimplanted  control steers, feed efficiency
was improved 16.8, 8.1, 28.7 and 16.8% for
steers implanted with Synovex, Finaplix,
Synovex plus Finaplix, and Revalor, re-
spectively.  No deleteriou s carcass traits were
seen for any implant treatment.
Ears were collected at slaughter and
evaluated  for abscesses.  Large implant-site
abscesses were noted for 2 of 16 steers
implanted with Synovex, 2 of 16 steers
implanted with Finaplix, and 1 of 8 steers
implanted with Revalor.  Blood levels of
estradiol  and TBA for steers with abscessed
implant sites did not deviate significantly
from treatment averages.
Regardless of mechanisms involved,
elevated serum concentrations of hormones
generally correlated well with period daily
gains by the steers (Figure 4), particularly for
SYN+FIN steers. No gain response from any
implant was seen in the last 28 days, despite
elevated serum levels of
TBA (REV, SYN+FIN, FIN) and estradiol
(REV). Lack of an implant response as cattle
approach slaughter has been observed in
other Kansas State research. This suggests
that finishing weight is nearing mature
weight, and little response should be
expected from anabolic agents. The impli-
cation is that, for yearlings fed for 120 days,
the time frame for an implant response may
be only about 90-100 days. A more rapid,
shorter-lived payout of anabolic agents may
promote faster, more efficient growth in this
instance.
Figure 1.  Serum Concentrations of Trenbolone Acetate
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Figure 2.  Serum Concentrations of Estradiol (E2)
Figure 3.  Plasma Urea Nitrogen (PUN) and Growth Hormone (GH) in Implanted Steers
Figure 4. Average Daily Gain (ADG) by Implanted Steers
2 0
